Conferences and Events > Previous Conferences and Events > 2019 Conferences and Events > 25th Annual Conference of the British HIV Association (Bournemouth 2019) >

25th Annual Conference of BHIVA - Poster Abstracts

Date: 2-5 April 2019

Venue: Bournemouth International Centre, UK

P1–P21 Antiretrovirals: Efficacy, Interactions and Pharmacokinetics

P1 A Phase 3, randomised, controlled clinical trial of bictegravir in a fixed-dose combination, B/F/TAF, versus ABC/DTG/3TC in treatment-naïve adults at week 96

P2 A review of patients’ medication history over a 2-month period in an HIV clinic

P3 An audit on the management of drug interactions between antiretroviral medicines and anticoagulants and/or antiplatelet medicines

P4 ARV switches with an undetectable viral load: why and when

P5 Audit: what happened to patients after Atripla was unbundled?

P6 B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment- naïve adults with high baseline viral load or low baseline CD4 cell count: week 96 results

P7 Comparative efficacy and safety of dolutegravir and lamivudine in treatment-naïve HIV patients

P8 Durable suppression and low rate of virological failures 3 years after switch to DTG+RPV two-drug regimen: SWORD 1 and 2 studies

P9 Experience of dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) two-drug antiretroviral regimens in a London tertiary centre

P10 From theory to reality: a clinic experience of Symtuza in complex patients

P11 Long-acting (LA), injectable ARVs: two case studies of compassionate access to LA cabotegravir and rilpivirine in young adults with perinatally acquired HIV-1 (PAHIV)

P12 Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week-48 results

P13 Modelling the long-term clinical outcomes of the novel single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the UK

P14 Patient perspectives on switching to generic antiretrovirals to reduce NHS costs

P15 Pragmatic use of darunavir/cobicistat (Rezolsta) monotherapy in poorly adherent patients

P16 Real-world experience of dolutegravir-containing dual antiretroviral (ARV) therapy in people living with HIV (PLWH): a retrospective analysis

P17 Seroconverters: then and now

P18 Switching Atripla to Truvada and generic efavirenz: is the saving sustainable?

P19 Tenofovir alafenamide versus tenofovir disoproxil fumarate in women: pooled analysis of seven clinical trials

P20 Transmitted NNRTI resistance does not impact the efficacy of EVG/c/FTC/TAF (or TDF) in two randomised clinical trials in treatment-naive patients living with HIV-1

P21 Virological failure after switch from twice-daily to once- daily raltegravir: a case series

P46–P86 Comorbidities, Co-infections and HIV/ART Complications

P46 ‘I’m 51 but living in the body of a 65-year old’: exploring the experiences and needs of those with HIV and multiple comorbidities

P47 A balance of risks: an audit of lipid and renal outcomes in patients prescribed tenofovir alafenamide

P48 A review of inpatients admitted with HIV encephalopathy in an inner-city London teaching hospital

P49 Accelerated atherosclerosis and myocardial injury in people living with HIV

P50 Anti-NMDA receptor encephalitis, a rare cause of acute confusion in an HIV-positive patient

P51 Antiretroviral central nervous system toxicity

P52 Assessment of bone health of women living with HIV aged>50 years in clinical practice: are we doing enough?

P53 Audit of type 2 diabetes in people living with HIV: performance against NICE guidelines targets

P54 Body composition, bone mineral density and metabolic parameters in well-controlled ART-experienced HIV-positive men

P55 Chronic liver disease assessment in HIV mono-infected individuals: HeAL (HIV non-virAl Liver disease) study update

P56 Clinical events and outcomes among an HIV-2 positive cohort in a central London HIV clinic

P57 Discontinuation of dolutegravir-containing regimens due to adverse reactions: real-world data

P58 Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF)

P59 FRAX is a good predictor of bone mineral density in people living with HIV of black ethnicity and/or low fracture risk

P60 Haemophagocytic lymphohistiocytosis in a UK adult population living with HIV

P61 Hepatic safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)

P62 Hepatitis HIV co-infection clinic: is a specialised service worth implementing in medium sized HIV cohorts?

P63 HIV is not associated with sleep-disordered breathing

P64 Homelessness among people living with HIV: a hospital inpatient cohort review

P65 Impact of application of new American hypertension guidelines to a UK HIV cohort

P66 Multimorbidity burden in an HIV population aged over 50 in South East England

P67 Neurological admissions in people living with HIV: a review of inpatient admissions to an inner-city teaching hospital

P68 No bones about it: high rates of osteoporosis in women living with HIV

P69 People living with HIV in the UK have a higher risk of progression to CNS disorders and other comorbidities than matched counterparts

P70 Poor virological control in young adults with perinatally acquired HIV (PAHIV): could modern antiretroviral therapy (ART) options provide a ray of hope for the future?

P71 Reclassification of renal failure using modified KDIGO classification and comparison between a UK versus Japanese HIV cohort

P72 Renal disease in HIV: early experience with tenofovir alafenamide in Worcestershire, UK

P73 Risk of hospitalisation in people living with HIV in the UK according to demographic, socioeconomic, mental health and lifestyle factors

P74 Routine IGRA testing of people with HIV provides few opportunities to prevent TB

P75 Routine monitoring of adults with HIV-1 over 40

P76 Switching to tenofovir alafenamide fumarate (TAF) in the over 60s: has it made a difference?

P77 Withdrawn.

P78 A changing pattern of HIV inpatient admissions and complexity: from late diagnoses to defaulters

P79 The prevalence of liver fibrosis in patients living with HIV with abnormal liver function tests

P80 The road to eliminating hepatitis C virus in individuals living with HIV

P81 The use of specific antiretroviral agents in persons with HIV with relative contraindications

P82 Trends in liver function test (LFT) derangement in those living with HIV: causes, consequences and considerations for future practice

P83 Utility of a medicines optimisation review (MOR) compared with standard pharmaceutical care in people with HIV on cART

P84 Utility of HCV core antigen for the diagnosis of acute HCV in high-risk individuals

P85 Waist:hip ratio (WHR): a better predictor of cardiovascular risk (CVR) than body mass index (BMI) in people living with HIV (PLWH)

P86 What is the significance of abnormal liver function tests in people living with HIV infection?

P87–P110 HIV Testing, Epidemiology and Surveillance

P87 A descriptive study of British South Asians living with HIV

P88 An audit of new HIV diagnoses in an urban setting of extremely high prevalence and missed opportunities for testing

P89 An evaluation of the national rollout of the HIV and AIDS Reporting System (HARS)

P90 Chemsex-related drug use and its association with health outcomes in men who have sex with men: a cross-sectional study of Antidote clinic service data

P91 Does setting of diagnosis impact time to link to HIV care following diagnosis in England, Wales and Northern Ireland?

P92 Frequent stable attenders: is HARS missing true complexity in stable patients?

P93 HIV testing in OPAT: a missed opportunity

P94 HIV testing survey to ascertain and encourage local compliance with NICE HIV testing guidelines

P95 Investigating HIV testing preferences in black, Latin American and other minority ethnicities to inform the co- design of digital vending machines for HIV self-testing kits

P96 Latin Americans in the UK: a key population for HIV prevention

P97 Mind the gap: new diagnoses of HIV in a London clinic (2016–2018)

P98 Mortality and causes of death among HIV patients in London in 2017

P99 New HIV diagnoses in a London sexual health clinic: missed opportunities?

P100 NHS healthcare utilisation of people living with HIV compared to matched, HIV-negative controls

P101 Opt-out HIV testing in the primary care setting: are our expectations realistic?

P102 Promoting and creating awareness of HIV/AIDS in the black African communities in Luton, United Kingdom

P103 Routine HIV testing in the Emergency Department in a major trauma centre: the first 8 weeks

P104 Routine HIV, hepatitis B and C testing in patients starting chemotherapy for solid organ tumours at a London district general hospital: screening uptake and management of results

P105 Routine opt-out HIV testing in gynaecological oncology pre- admission clinic

P106 Substantial decline in HIV incidence between 2015 and 2018 among a prospective cohort of men who have sex with men in England

P107 Their story, your choice: a series of interactive films aimed at targeting HIV stigma in black African communities in the UK. Funded by Comic Relief and the MAC AIDS Fund

P108 UNAIDS 90-90-90 targets are achievable in small urban clinics

P109 Understanding the factors that influence late HIV diagnosis: a retrospective review

P110 What can be learnt from mapping new HIV diagnoses across a high prevalence city?

P111–P124 Psychosocial Issues and Quality of Life

P111 A sexual empowerment group for women living with HIV

P112 An evaluation of quality of life through educational, vocational and housing outcomes for adults living with perinatally acquired HIV

P113 Association with side effects to antiretroviral treatment and health-related quality of life: a population study of people living with HIV in England and Wales

P114 Disability prevalence, domains and associations with age, among people living with HIV accessing routine outpatient HV care in London, UK: a cross-sectional self-report study

P115 Evaluation of the psychometric properties of the HIV Disability Questionnaire (HDQ) among adults living with HIV in London, UK: a cross-sectional self-report measurement study

P116 Factors associated with depressive symptoms among women living with HIV (WLHIV) in England, 2017: data from the 2017 Positive Voices survey

P117 Healthcare needs beyond HIV in a changing NHS: participant exploration of Positive Voices data

P118 Improving patient engagement and medication adherence in young adults with perinatally acquired HIV (PAHIV)

P119 New models of care with specialist women’s clinics can provide better support for women living with HIV

P120 Patient-reported outcomes among adults living with HIV-1 who were randomly allocated to B/F/TAF versus DTG/ABC/ 3TC in two Phase 3 controlled clinical trials over 48 weeks

P121 Psychosocial factors affecting mortality in patients living with HIV: a retrospective audit and case presentation

P122 Quality of life along the continuum of care for HIV in England

P123 The unmet mental health needs of people living with HIV: participant exploration of the Positive Voices data

P124 Use of peer-led research design model in HIV policy research

P125–P146 Service Development, Education and Training

P125 A human rights approach to successfully change national aviation laws to enable people living with HIV to train as pilots

P126 An audit on accuracy of baseline investigations on newly diagnosed adult HIV-1-positive individuals

P127 Annual viral load monitoring in virologically suppressed patients

P128 Antiretroviral use in the Midlands and East of England: baseline data on over 10,000 HIV-positive patients

P129 Audit review: adherence to the national recommendation of annual cervical screening for women living with HIV, 2015–2018

P130 Can patient satisfaction be maintained after provider switch?

P131 Designing Looped In: using qualitative research in the development of an online tool to support interpersonal communication on HIV

P132 Disclosures: rewriting the narrative about HIV through creative activism

P133 Do HIV patients find remote services acceptable? A survey of attitudes towards digital HIV care

P134 Don’t forget the DNA: a descriptive analysis of female patients who do not attend HIV clinic appointments and their uptake of annual cervical smears

P135 Enhancing service quality for stable HIV patients through nurse-led, technology-enabled annual review clinics

P136 Identification of the frailty syndrome in people living with HIV (PLHIV) using a multiple deficit model

P137 Improving testosterone testing in people living with HIV

P138 Meaningful involvement to design solutions for ensuring people living with HIV live well into older age

P139 Measuring the impact of specialist HIV community nursing

P140 Missed doses of antiretroviral therapy in the context of acute admissions to hospital for HIV-positive patients: an audit conducted retrospectively across 2 months of acute admissions in Brighton

P141 Patient recommendations for developing care pathways for HIV-related metabolic comorbidities

P142 Tenofovir alafenamide (TAF) for treatment of HIV-1 in adults and adolescents: a provincial audit

P143 The East London Immediate ART (ELIA) survey: attitudes and barriers to immediate ART initiation

P144 The family HIV testing pathway: ensuring prioritisation and follow up

P145 The impact of weather and college holidays on attendance at HIV youth services

P146 Vaccinations in newly diagnosed HIV patients: a quality improvement project

P147–P151 STIs, Reproductive Health, Contraception and Sexual Dysfunction

P147 A review of hypogonadism in an HIV cohort

P148 Evaluation of a dedicated postnatal contraception clinic for women living with HIV (WLWH): 5 years post- implementation

P149 Feasibility, acceptability and outcomes of fertility evaluation in adults with perinatally acquired HIV-1 infection: a cross- sectional observational study

P150 Is it time to review the recommended intervals of cervical cytology in women living with HIV (WLHIV)?

P151 The menopause experience: a quality improvement project